Stocktoria
AMARIN CORP PLCUK AMRN
AMARIN CORP PLCUK (AMRN) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $213.6M at a -18.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.679 |
| Retained earnings / assets | -2.545 |
| EBIT / assets | -0.075 |
| Equity / liabilities | 2.172 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| AMRN | AMARIN CORP PLCUK | 5/9 | -2.07 | — | -6.5% |
| VNDA | Vanda Pharmaceuticals Inc. | 2/9 | 0.13 | — | +8.7% |
| IDYA | IDEAYA Biosciences, Inc. | 3/9 | 12.9 | — | — |
| PBYI | PUMA BIOTECHNOLOGY, INC. | 6/9 | -14.13 | 13.3 | -0.9% |
| LFVN | Lifevantage Corp | 6/9 | -0.45 | 8.5 | +14.2% |
| ANAB | ANAPTYSBIO, INC | 5/9 | -0.3 | — | +157% |
| AKBA | Akebia Therapeutics, Inc. | 5/9 | -12.49 | — | +47.5% |
About AMARIN CORP PLCUK
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
FAQ
Is AMRN financially healthy?
AMARIN CORP PLCUK's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does AMRN pay a dividend?
No, AMARIN CORP PLCUK does not currently pay a dividend.
How profitable is AMRN?
In FY2025, AMARIN CORP PLCUK had a net margin of -18.2% and a return on equity of -8.4%.
What is the analyst price target for AMRN?
The average Wall-Street price target for AMARIN CORP PLCUK is $12.50, about 11.1% below the recent price, from 2 analysts.
Is AMRN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on AMARIN CORP PLCUK: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.